Further reports show that MET-mediated resistance to EGFR TKI treatment could be overcome by inhibition of PI3K alone or in conjunction with erlotinib in vitro and in vivo.60 It really is unclear whether EGFR-mutant cells acquire MET amplification or whether
So far, there is absolutely no proof a meaningful survival benefit because of novel targeted agents clinically
So far, there is absolutely no proof a meaningful survival benefit because of novel targeted agents clinically. Regarding low ORR appallingly, the question is whether disease stabilizations are treatment related or reflecting the organic span of disease 13 simply. 39/841